ANA. I. Nilov

A. I. Nilov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. I. Nilov has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding the indications of cladribine tablets for multiple sclerosis: From early use in treatment-naive patients to the possibility of retreatment courses after 4 years of cladribine initiation therapy

    by E. V. Popova, N. V. Khachanova, M. V. Abroskina, M. V. Davydovskaya, E. P. Evdoshenko, M. V. Shumilina, D. S. Korobko, A. I. Nilov, M. V. Sutormin, Yu. V. Trinitatskiy, et al.

    Autoimmune disorders are common clinical conditions that result from an abnormal immune response to the body’s own structures. Most existing immunomodulatory drugs for multiple sclerosis (MS) therapy are capable of suppressing autoimmune reactions as long as they are used, but they do not target autoreactive immunological memory and cannot disable the underlying mechanisms to induce remission without therapy. Over the past decade, there has been an increased interest in highly effective immune reconstruction therapy (IRT), which can transiently or persistently provoke the immune system resetting. Cladribine (2-chloro-deoxyadenosine) in tablets belongs to the group of IRT drugs for relapsing multiple sclerosis (RMS), which therapy consists of two short courses of treatment during the 1st and 2nd year. Most patients achieve sustained efficacy with the use of cladribine, but a small proportion of patients may experience new disease activity that requires the treating physician to make a decision regarding a previously chosen treatment strategy. Since cladribine tablets were approved by the European Union, USA and Russia more than 5 years ago, the number of publications devoted to the analysis of real-world practice has been steadily increasing. The purpose of this publication is to present the results of Expert Council conducted in February 2026. The participants of the expert council developed further recommendations for the administration of the drug to therapeutically naive patients with relapsing-remitting MS, in secondary progressive MS with exacerbations, algorithms for managing patients with RMS with disease activity reactivation after the initial 2 courses of therapy with cladribine and subsequent follow-up, and discussed the profiles of patients in whom switching to cladribine tablets is considered as an option that reduces the risks of prolonged immunosuppression.

  • Open Access

    Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential

    by V. S. Krasnov, Ya. V. Vlasov, E. Р. Evdoshenko, D. S. Korobko, V. М. Lebedev, I. G. Lukashevich, A. I. Nilov, E. S. Novikova, E. V. Popova, K. V. Sapozhnikov, et al.

    Neuromyelitis optica spectrum disorders (NMOSD) are a group of inflammatory diseases of the central nervous system. B-lymphocytes play leading role in their pathogenesis in most cases. СD20 surface antigen is one of the B-lymphocytes makers. There is extensive world experience with chimeric monoclonal anti-CD20 antibody rituximab off-label using for NMOSD exacerbations prevention. It has been included in published international and Russian algorithms for NMOSD treatment along with other approved medications. Divozilimab is recombinant humanized anti-CD20 monoclonal antibody with a modified glycosylation pattern of Fc-fragment which is approved in Russian Federation for the treatment of multiple sclerosis, systemic scleroderma and also for NMOSD (September 2025). The publication is intended to present the results of the Russian Expert Councils work in September 2025 and February 2026. According to the analysis of publications on anti-CD20 NMOSD therapy, the 6-month results of divozilimab study BCD-132-6/AQUARELLE (NCT05730699) and data of additional subanalysis experts agreed the profiles of NMOSD patients for divozilimab therapy, time to full therapeutic effect and monitoring plan during treatment with divozilimab. Experts supplemented the algorithm for initial prescription and switching of medications for prevention of NMOSD attacks in patients with AQP4-IgG aged 18 years and older, agreed on the algorithm for the administration of medications for prevention of NMOSD attack in patients without AQP4-IgG aged 18 years and older, determined positions of divozilimab in both algorithms. According to experts opinion divozilimab appears as promising treatment option in NMOSD. Analysis of divozilimab effectiveness and safety long-term results in BCD-132-6/AQUARELLE study and real-world practice will be important steps toward clarifying and potentially extending patient profiles.

  • Open Access

    Experience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation

    by V. S. Krasnov, M. P. Abramova, M. A. Bakalova, A. I. Bezvodinskikh, R. Ts. Bembeeva, Z. S. Gasanova, E. P. Evdoshenko, N. V. Zhukovskaya, O. V. Zaplakhova, S. P. Ivanova, et al.

    Introduction . Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP). Aim . To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP. Materials and methods . The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed. Results . Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety. Conclusions . The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.

  • Open Access

    Results of medical and social research and assessment of quality of life in myasthenia gravis

    by Ya. V. Vlasov, Yu. A. Merkulov, V. M. Alifirova, M. V. Ambroskina, K. Z. Bakhtiyarova, S. B. Blinova, Z. A. Goncharova, N. Yu. Gorokhova, I. V. Greshnova, L. G. Zaslavsky, et al.

    Myasthenia gravis (MG) is one of the most common autoimmune diseases of the nervous system. Medical and social analysis of the patient population structure and assessment of their quality of life (QoL) as one of the criteria for the effectiveness of treatment are of great importance for evaluating the condition of patients and the directions of development of specialised care.Objective: to analyse the quality of life of patients diagnosed with MG.Material and methods. The study involved 662 patients with MG from 26 regions of Russia. A specially designed medical and social questionnaire and the SF-36 questionnaire were used.Results. In Russia, women and middle-aged and elderly people predominate among MG patients. MG is characterised by a relatively favourable course (less than half of patients have any form of disability). Almost two-thirds of patients have other chronic diseases. About 90% of MG patients receive drug therapy, but almost half of patients have problems obtaining their prescribed medication. In addition to a significant decrease in physical activity, there is also a decrease in the mental state of patients associated with various physical disorders, as well as fear of the future (fear of symptom recurrence, risk of being left without support and unable to perform daily tasks, the need for lifelong treatment). Among the symptoms of MG that affect the emotional state of patients, weakness and rapid fatigue are in first place, followed by bulbar dysfunction. The role functioning of patients with MG depends to a greater extent on their physical condition and to a lesser extent on their emotional state. Those receiving regular drug therapy had significantly better indicators than those who were not treated. The SF-36 scale assessment confirmed that physical condition and physical functioning, which influence the psychological components of QoL assessment, are crucial for QoL in MG.Conclusion. A significant decrease in QoL indicators was noted in MG, primarily in the physical component and, secondarily, in psychological health. All this points to the need for early initiation of highly effective pathogenetic therapy, in particular with modern C5-complement inhibitors.


  • Open Access

    Neuromyelitis optica spectrum disorders, terminology and therapeutic issues: amended consensus opinion

    by V. S. Krasnov, Yu. V. Vlasov, E. P. Evdoshenko, D. S. Korobko, M. D. Matson, A. I. Nilov, A. A. Sokolova, N. A. Totolian, N. V Khachanova, M. V. Shumilina, et al.

    In Russian Federation in 2022, the Expert Council adopted the main definitions and terms for neuromyelitis optica spectrum disorders (NMOSD) and proposed a treatment algorithm for patients with NMOSD with antibodies to aquaporin-4 (AQP4-IgG). The publication is intended to present the results of the work of the Russian Expert Council in September 2024. The experts agreed on clarifications of previously published terminology, new definitions, current issues in the therapy of NMOSD, proposed profiles of patients with NMOSD for ravulizumab and a monitoring plan during treatment with this drug, and agreed on an updated algorithm for prescribing medications that prevent exacerbations in patients with NMOSD with AQP4-IgG aged 18 years and older.


  • Open Access

    Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion

    by E. V. Popova, М. В. Аброськина, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaia, E. P. Evdoshenko, D. S. Korobko, A. I. Nilov, M. V. Sutormin, Yu. V. Trinitatskiy, et al.

    In March 2020, oral cladribine was licensed in Russian Federation for the treatment of adult patients with highly active relapsing multiple sclerosis as defined by clinical or imaging features. Three years after the introduction into the Russian market, practical aspects in the use of cladribine tablets we evaluated, including data from real-world studies and the experience gained in the own routine clinical practice. Early initiation of cladribine therapy, use of cladribine in treatment naïve patients and patients with suboptimal response to previous disease-modifying therapy, use of cladribine as the treatment of choice in patients with suboptimal response to platform disease-modifying therapy and washout period while switching to cladribine from other disease-modifying therapy. During the discussion thirteen neurologists from federal and regional centers experienced in multiple sclerosis diagnosis and therapy were asked to answer several questions regarding the practical use of cladribine tables and come to consensus opinion. Consent was reached if at least 75% of the experts agreed on a particular statement. The experts agreed on the possibility to switch patients to cladribine from platform disease-modifying therapy in case of MRI activity or neutralizing antibodies in the absence of relapses activity to achieve better disease control, potential cladribine effects on progression independent of relapses, washout period reduction while switching from natalizumab to cladribine. Consensus opinion will help to manage practical questions regarding cladribine usage.


  • Open Access

    Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis

    by K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, et al.

    Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with MS-modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during therapy with other MSMDs. A group of expert neurologists from various clinics in Russia, who actively participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects of using the tablets of cladribine registered in Russia in March 2020 for the treatment of patients with HAMS. The paper mentions the groups of patients in whom the drug, an examination before starting a therapy cycle, routes of administration, and dose, and a monitoring scheme during and after treatment cycles are indicated. This drug acts on the principle of selective immunoreconstitution and may occupy an important place in the treatment of HAMS.